Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

The Impact of Palliative Care Interventions on Medication Regimen Complexity.

Walter KS, Gillespie H, Moqbel D, Choe HM, Smith MA.

J Palliat Med. 2020 Feb;23(2):156-157. doi: 10.1089/jpm.2019.0229. No abstract available.

PMID:
32023191
2.

The Ensemble Mars Atmosphere Reanalysis System (EMARS) Version 1.0.

Greybush SJ, Kalnay E, Wilson RJ, Hoffman RN, Nehrkorn T, Leidner M, Eluszkiewicz J, Gillespie HE, Wespetal M, Zhao Y, Hoffman M, Dudas P, McConnochie T, Kleinböhl A, Kass D, McCleese D, Miyoshi T.

Geosci Data J. 2019 Nov;6(2):137-150. doi: 10.1002/gdj3.77. Epub 2019 Aug 23.

3.

Experience Based Learning (ExBL): Clinical teaching for the twenty-first century.

Dornan T, Conn R, Monaghan H, Kearney G, Gillespie H, Bennett D.

Med Teach. 2019 Oct;41(10):1098-1105. doi: 10.1080/0142159X.2019.1630730. Epub 2019 Aug 6.

PMID:
31382787
4.

Emergency management of massive haemoptysis.

Heijkoop B, Gillespie H, Kiroff G.

BMJ Case Rep. 2019 Jan 29;12(1). pii: e225620. doi: 10.1136/bcr-2018-225620.

PMID:
30700450
5.

How can tomorrow's doctors be more caring? A phenomenological investigation.

Gillespie H, Kelly M, Gormley G, King N, Gilliland D, Dornan T.

Med Educ. 2018 Oct;52(10):1052-1063. doi: 10.1111/medu.13684.

PMID:
30255523
6.

Transplant Medication Management for Patients Nearing End of Life #333.

Gillespie H, Smith MA, O'Neil TA.

J Palliat Med. 2017 Aug;20(8):895-896. doi: 10.1089/jpm.2017.0247. No abstract available.

PMID:
28777715
7.

How do patients experience caring? Scoping review.

Gillespie H, Kelly M, Duggan S, Dornan T.

Patient Educ Couns. 2017 Sep;100(9):1622-1633. doi: 10.1016/j.pec.2017.03.029. Epub 2017 Mar 31. Review.

PMID:
28392179
8.

The Secreted Protease PrtA Controls Cell Growth, Biofilm Formation and Pathogenicity in Xylella fastidiosa.

Gouran H, Gillespie H, Nascimento R, Chakraborty S, Zaini PA, Jacobson A, Phinney BS, Dolan D, Durbin-Johnson BP, Antonova ES, Lindow SE, Mellema MS, Goulart LR, Dandekar AM.

Sci Rep. 2016 Aug 5;6:31098. doi: 10.1038/srep31098.

9.

Corrigendum: The Type II Secreted Lipase/Esterase LesA is a Key Virulence Factor Required for Xylella fastidiosa Pathogenesis in Grapevines.

Nascimento R, Gouran H, Chakraborty S, Gillespie HW, Almeida-Souza HO, Tu A, Rao BJ, Feldstein PA, Bruening G, Goulart LR, Dandekar AM.

Sci Rep. 2016 Feb 25;6:21575. doi: 10.1038/srep21575. No abstract available.

10.

The Type II Secreted Lipase/Esterase LesA is a Key Virulence Factor Required for Xylella fastidiosa Pathogenesis in Grapevines.

Nascimento R, Gouran H, Chakraborty S, Gillespie HW, Almeida-Souza HO, Tu A, Rao BJ, Feldstein PA, Bruening G, Goulart LR, Dandekar AM.

Sci Rep. 2016 Jan 12;6:18598. doi: 10.1038/srep18598. Erratum in: Sci Rep. 2016;6:21575.

11.

Arrhythmias in structural heart disease.

Gillespie HS, Lin CC, Prutkin JM.

Curr Cardiol Rep. 2014 Aug;16(8):510. doi: 10.1007/s11886-014-0510-7. Review.

PMID:
24950672
12.

Pulmonary contusion in a football player.

Gillespie H, Sisson R, DiFiori JP.

Curr Sports Med Rep. 2013 Mar-Apr;12(2):57-8. doi: 10.1249/JSR.0b013e318287469e. No abstract available.

PMID:
23478553
13.

Dietary selenium fails to influence cigarette smoke-induced lung tumorigenesis in A/J mice.

Glauert HP, Martin JB, Li J, Tharappel JC, Han SG, Gillespie HD, Cantor AH, Lee EY, Gairola CG.

Cancer Lett. 2013 Jun 28;334(1):127-32. doi: 10.1016/j.canlet.2012.11.047. Epub 2012 Dec 5.

14.

Update on the management of patellar instability.

Gillespie H.

Curr Sports Med Rep. 2012 Sep-Oct;11(5):226-31. doi: 10.1249/JSR.0b013e3182698931.

PMID:
22965344
15.

Noninvasive diagnosis of chemotherapy related cardiotoxicity.

Gillespie HS, McGann CJ, Wilson BD.

Curr Cardiol Rev. 2011 Nov;7(4):234-44. Review.

16.

A questionnaire to measure melanoma risk, knowledge and protective behaviour: assessing content validity in a convenience sample of Scots and Australians.

Gillespie HS, Watson T, Emery JD, Lee AJ, Murchie P.

BMC Med Res Methodol. 2011 Aug 25;11:123. doi: 10.1186/1471-2288-11-123.

17.

Osteochondroses and apophyseal injuries of the foot in the young athlete.

Gillespie H.

Curr Sports Med Rep. 2010 Sep-Oct;9(5):265-8. doi: 10.1249/JSR.0b013e3181f19488. Review.

PMID:
20827090
18.
19.

Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrow endothelial cells.

Hill A, McFarlane S, Mulligan K, Gillespie H, Draffin JE, Trimble A, Ouhtit A, Johnston PG, Harkin DP, McCormick D, Waugh DJ.

Oncogene. 2006 Oct 5;25(45):6079-91. Epub 2006 May 1.

PMID:
16652145
20.

Racial disparities in health between white and African American family practice patients: clinical implications.

Coeytaux RR, Gillespie HM, Callahan LF, Kaufman JS, Plescia M, Williams C, Sloane PD.

N C Med J. 2004 Nov-Dec;65(6):330-4.

PMID:
15714720
21.

The effects of high ambient glucose on the radiosensitivity of retinal microvascular endothelial cells and pericytes.

Patton W, Gillespie H, Frew L, Burns M, Lewis S, Chakravarthy U.

Curr Eye Res. 2002 Jan;24(1):51-7.

PMID:
12187495
22.

Epidermal growth factor up-regulates CD44-dependent astrocytoma invasion in vitro.

Monaghan M, Mulligan KA, Gillespie H, Trimble A, Winter P, Johnston PG, McCormick D.

J Pathol. 2000 Dec;192(4):519-25.

PMID:
11113870
23.

Epidemiological relatedness and clonal types of natural populations of Escherichia coli strains producing Shiga toxins in separate populations of cattle and sheep.

Beutin L, Geier D, Zimmermann S, Aleksic S, Gillespie HA, Whittam TS.

Appl Environ Microbiol. 1997 Jun;63(6):2175-80.

24.

Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication.

Volkow ND, Gillespie H, Mullani N, Tancredi L, Grant C, Valentine A, Hollister L.

Psychiatry Res. 1996 May 31;67(1):29-38.

PMID:
8797240
25.

Brain glucose metabolism in violent psychiatric patients: a preliminary study.

Volkow ND, Tancredi LR, Grant C, Gillespie H, Valentine A, Mullani N, Wang GJ, Hollister L.

Psychiatry Res. 1995 Nov 10;61(4):243-53.

PMID:
8748468
26.

Drugs for cocaine dependence: not easy.

Hollister LE, Krajewski K, Rustin T, Gillespie H.

Arch Gen Psychiatry. 1992 Nov;49(11):905-6. No abstract available.

PMID:
1444730
27.

The effect of haloperidol on aldosterone secretion.

Warner MD, Gillespie H, Pavlou SN, Nader S, Peabody CA.

Psychoneuroendocrinology. 1992 Oct;17(5):517-21.

PMID:
1484918
28.

Cerebellar metabolic activation by delta-9-tetrahydro-cannabinol in human brain: a study with positron emission tomography and 18F-2-fluoro-2-deoxyglucose.

Volkow ND, Gillespie H, Mullani N, Tancredi L, Grant C, Ivanovic M, Hollister L.

Psychiatry Res. 1991 May;40(1):69-78.

PMID:
1658842
29.

Human urinary excretion profile after smoking and oral administration of [14C]delta 1-tetrahydrocannabinol.

Johansson E, Gillespie HK, Halldin MM.

J Anal Toxicol. 1990 May-Jun;14(3):176-80.

PMID:
2165199
30.
31.

Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana.

Johansson E, Halldin MM, Agurell S, Hollister LE, Gillespie HK.

Eur J Clin Pharmacol. 1989;37(3):273-7.

PMID:
2558889
32.

Single-dose kinetics of deuterium-labelled cannabinol in man after intravenous administration and smoking.

Johansson E, Ohlsson A, Lindgren JE, Agurell S, Gillespie H, Hollister LE.

Biomed Environ Mass Spectrom. 1987 Sep;14(9):495-9.

PMID:
2960395
33.

Human pharmacology of 1S and 1R enantiomers of delta-3-tetrahydrocannabinol.

Hollister LE, Gillespie HK, Mechoulam R, Srebnik M.

Psychopharmacology (Berl). 1987;92(4):505-7.

PMID:
2819920
34.

Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man.

Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, Hollister L.

Pharmacol Rev. 1986 Mar;38(1):21-43. Review. No abstract available.

PMID:
3012605
35.

Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration.

Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister LE.

Biomed Environ Mass Spectrom. 1986 Feb;13(2):77-83.

PMID:
2937482
36.

Clinical evaluation of a naltrexone sustained-release preparation.

Chiang CN, Hollister LE, Gillespie HK, Foltz RL.

Drug Alcohol Depend. 1985 Sep;16(1):1-8.

PMID:
4064907
37.

Mood alteration following oral and intravenous haloperidol and relationship to drug concentration in normal subjects.

Magliozzi JR, Gillespie H, Lombrozo L, Hollister LE.

J Clin Pharmacol. 1985 May-Jun;25(4):285-90.

PMID:
4008674
38.

Yohimbine and the model anxiety state.

Henauer SA, Gillespie HK, Hollister LE.

J Clin Psychiatry. 1984 Dec;45(12):512-5.

PMID:
6501237
39.

Contrasts between Japanese and American medical education and clinical practice.

Gillespie CA, Gillespie HE, Carr JE.

Mil Med. 1984 Jul;149(7):393-6. No abstract available.

PMID:
6431324
40.

Hemolyzed blood and serum levels of delta 9-THC: effects on the performance of roadside sobriety tests.

Reeve VC, Robertson WB, Grant J, Soares JR, Zimmermann EG, Gillespie HK, Hollister LE.

J Forensic Sci. 1983 Oct;28(4):963-71.

PMID:
6313846
41.

Plasma concentrations of delta-9-tetrahydrocannabinol and impaired motor function.

Reeve VC, Grant JD, Robertson W, Gillespie HK, Hollister LE.

Drug Alcohol Depend. 1983 Apr;11(2):167-75.

PMID:
6305619
42.

Theophylline antagonizes diazepam-induced psychomotor impairment.

Henauer SA, Hollister LE, Gillespie HK, Moore F.

Eur J Clin Pharmacol. 1983;25(6):743-7.

PMID:
6662173
43.

Single dose kinetics of deuterium labelled delta 1-tetrahydrocannabinol in heavy and light cannabis users.

Ohlsson A, Lindgren JE, Wahlén A, Agurell S, Hollister LE, Gillespie HK.

Biomed Mass Spectrom. 1982 Jan;9(1):6-10.

PMID:
6277407
44.

Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography.

Agurell S, Carlsson S, Lindgren JE, Ohlsson A, Gillespie H, Hollister L.

Experientia. 1981 Oct 15;37(10):1090-2. No abstract available.

PMID:
6273208
45.

Aversive effects of naltrexone in subjects not dependent on opiates.

Hollister LE, Johnson K, Boukhabza D, Gillespie HK.

Drug Alcohol Depend. 1981 Aug;8(1):37-41.

PMID:
7297411
46.

Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication?

Hollister LE, Gillespie HK, Ohlsson A, Lindgren JE, Wahlen A, Agurell S.

J Clin Pharmacol. 1981 Aug-Sep;21(S1):171S-177S.

PMID:
6271822
47.

Plasma levels of delta 9-tetrahydrocannabinol after intravenous, oral, and smoke administration.

Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK.

NIDA Res Monogr. 1981 Feb;34:250-6. No abstract available.

PMID:
6261133
48.

Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis.

Lindgren JE, Ohlsson A, Agurell S, Hollister L, Gillespie H.

Psychopharmacology (Berl). 1981;74(3):208-12.

PMID:
6267648
49.

An operation for anteromedial rotatory instability of the knee. A preliminary report.

Gillespie HS.

J Bone Joint Surg Br. 1980 Nov;62-B(4):457-9.

PMID:
7430224
50.

Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking.

Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK.

Clin Pharmacol Ther. 1980 Sep;28(3):409-16.

PMID:
6250760

Supplemental Content

Loading ...
Support Center